단장증후군 시장 : 치료법별, 투여 경로별, 환자 연령별, 병인별, 최종 용도별 - 세계 시장 예측(2026-2032년)

The Short Bowel Syndrome Market is projected to grow by USD 2.31 billion at a CAGR of 9.50% by 2032.

Short bowel syndrome (SBS) is a rare, high-burden intestinal failure condition caused by inadequate absorptive capacity after major bowel resection, congenital bowel loss, or severe functional impairment. It is strongly associated with dependence on parenteral nutrition or intravenous fluids, recurrent dehydration, electrolyte imbalance, catheter-related bloodstream infection, kidney complications, and intestinal failure-associated liver disease.

For pharmaceutical and biotechnology stakeholders, the short bowel syndrome market is defined by orphan-disease economics, specialized prescribing, and measurable clinical endpoints such as reduced parenteral support volume, fewer infusion days, improved hydration, and intestinal adaptation. FDA- and EMA-approved teduglutide established GLP-2 analog therapy as a validated pathway for eligible adults and pediatric patients, while next-generation enteroendocrine, microbiome, and regenerative approaches are reshaping long-term SBS treatment strategies.

Transformative Shifts in the SBS Treatment Landscape

The SBS landscape is shifting from lifelong nutritional replacement toward targeted intestinal rehabilitation. Multidisciplinary care models now combine diet optimization, oral rehydration strategies, anti-motility therapy, acid suppression, micronutrient management, home parenteral nutrition, surgical reconstruction, and GLP-2-based pharmacotherapy to reduce dependence on parenteral support.

Innovation is also moving toward longer-acting peptides, pediatric-friendly formulations, real-world evidence generation, and earlier intervention after bowel resection. Commercial success increasingly depends on demonstrating durability, safety in chronic use, reduction in hospital utilization, lower catheter-related complication burden, and compatibility with established intestinal failure programs.

Cumulative Impact of Artificial Intelligence on SBS Innovation

Artificial intelligence is becoming increasingly relevant across SBS drug development and commercialization. AI-enabled literature mining, biomarker discovery, digital phenotyping, and trial feasibility modeling can help identify high-risk subgroups, optimize inclusion criteria, and accelerate recruitment in a rare disease where patient numbers are limited and care is concentrated in specialist centers.

In clinical and commercial settings, AI can support parenteral nutrition optimization, adverse event prediction, electronic health record screening, remote monitoring, and real-world evidence analytics. The highest-value use cases are those that improve patient monitoring while preserving clinician oversight, data privacy, interoperability, and regulatory-grade validation.

Key Regional Insights Across Global SBS Care

North America remains a leading SBS treatment region due to established home parenteral nutrition infrastructure, orphan-drug pathways, specialty pharmacy networks, payer experience with rare-disease therapies, and a high concentration of intestinal rehabilitation centers. Europe benefits from cross-border clinical expertise, national intestinal failure services, and EMA-recognized SBS therapies, although reimbursement timing, health technology assessment outcomes, and access to home parenteral nutrition vary by country.

Asia-Pacific is gaining relevance as Japan, China, Australia, South Korea, and India expand advanced gastroenterology, pediatric surgery, clinical nutrition, and tertiary hospital capabilities. Latin America shows growing need for SBS care in Mexico, Brazil, and other urban referral settings, but access is shaped by public-private reimbursement gaps and specialized nutrition support capacity. The Middle East, particularly Gulf health systems, is investing in specialty care and hospital infrastructure, while Africa faces a larger access barrier due to limited intestinal failure centers, uneven parenteral nutrition availability, infection-control challenges, and constrained reimbursement for orphan therapies.

Key Group Insights for SBS Market Access

Within the European Union, centralized regulatory pathways and national health technology assessments influence the adoption of GLP-2 analogs and home parenteral nutrition services, making country-level evidence packages essential for access. G7 markets typically offer stronger rare-disease infrastructure, specialist referral pathways, home-care services, and pharmacovigilance systems that support premium SBS therapies when they demonstrate clinically meaningful reductions in parenteral support.

ASEAN and BRICS countries represent long-term opportunities as tertiary hospitals expand gastrointestinal surgery, pediatric care, and clinical nutrition programs, although access remains uneven between major urban centers and broader public health systems. GCC markets are investing in advanced specialty care, international clinical standards, and hospital-based nutrition support, while NATO countries broadly benefit from resilient medical supply chains, established hospital procurement systems, and emergency preparedness frameworks relevant to parenteral nutrition, infusion supplies, and SBS therapy continuity.

Key Country Insights for SBS Market Prioritization

The United States leads SBS commercialization through orphan-drug incentives, specialist intestinal failure centers, home infusion networks, and specialty pharmacy distribution. Canada emphasizes evidence-based reimbursement and provincial access pathways, while Mexico and Brazil are building access through tertiary hospitals, gastroenterology referral centers, and private-sector specialty care. The United Kingdom, Germany, France, Italy, and Spain have strong gastroenterology and clinical nutrition expertise, but differ in reimbursement speed, regional budget controls, home parenteral nutrition organization, and health technology assessment requirements.

Russia's access environment is influenced by localized procurement and specialty-care concentration in major cities. China and India offer significant unmet clinical need but uneven access to home parenteral nutrition, rare-disease reimbursement, and specialized intestinal rehabilitation services outside leading tertiary hospitals. Japan, Australia, and South Korea provide mature specialist networks, high-quality clinical governance, and established pathways for high-evidence therapies that reduce parenteral support burden and improve long-term SBS management.

Actionable Recommendations for SBS Industry Leaders

Industry leaders should prioritize evidence packages that connect SBS therapies to reduced parenteral nutrition volume, fewer infusion days, improved fluid balance, lower catheter complication risk, reduced hospitalization burden, and quality-of-life improvement. Outcomes should be measured through registries, long-term extension studies, patient-reported outcomes, and real-world evidence from intestinal failure centers.

Stakeholders should also build integrated access strategies covering specialist education, nutrition-team partnerships, home-care coordination, pediatric transition support, adherence services, and payer-ready health economic evidence. In rare SBS populations, durable leadership will depend on trust, safety transparency, evidence continuity, and practical support across diagnosis, treatment initiation, long-term monitoring, and home-based care.

Research Methodology for SBS Market Analysis

This executive summary is based on a structured review of publicly available clinical, regulatory, and healthcare delivery evidence related to short bowel syndrome, intestinal failure, parenteral nutrition, GLP-2 analog therapy, pediatric and adult care pathways, and regional access dynamics. Sources considered include regulatory approvals, clinical guidelines, peer-reviewed literature, health technology assessment principles, and rare-disease care infrastructure indicators.

Insights were synthesized using a triangulated approach that compares therapeutic standards, reimbursement conditions, regional healthcare capacity, clinical endpoint relevance, and stakeholder needs. The analysis avoids unverified market sizing, market share, and forecasting claims, and emphasizes evidence-backed drivers that shape clinical adoption, access, and commercialization strategy.

Conclusion: Strategic Outlook for Short Bowel Syndrome

Short bowel syndrome is evolving from a replacement-care condition into a targeted intestinal rehabilitation market. The clinical goal is no longer limited to survival on parenteral nutrition; it increasingly includes intestinal adaptation, fewer complications, improved independence, better hydration, and sustainable long-term outcomes.

For pharmaceutical innovators, the most attractive opportunities are therapies and support models that reduce parenteral dependence, demonstrate durable benefit, and integrate seamlessly into specialist SBS care. Evidence quality, access planning, home-care coordination, and patient-centered implementation will define competitive advantage in this rare and highly specialized treatment landscape.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Short Bowel Syndrome Market, by Treatment Type

• 7.1. Nutritional Support
  • 7.1.1. Parenteral Nutrition
  • 7.1.2. Enteral Nutrition
• 7.2. Pharmacological Treatment
  • 7.2.1. GLP-2 Analogues
  • 7.2.2. Growth Hormone Therapy
  • 7.2.3. Glutamine Therapy
  • 7.2.4. Antibiotics
• 7.3. Surgical Treatment
  • 7.3.1. Intestinal Lengthening Procedures
  • 7.3.2. Intestinal Transplantation

8. Short Bowel Syndrome Market, by Route Of Administration

• 8.1. Parenteral
  • 8.1.1. Intravenous
  • 8.1.2. Subcutaneous
• 8.2. Oral

9. Short Bowel Syndrome Market, by Patient Age

• 9.1. Adult
• 9.2. Geriatric
• 9.3. Pediatric

10. Short Bowel Syndrome Market, by Etiology

• 10.1. Trauma
• 10.2. Crohn's Disease
• 10.3. Mesenteric Ischemia
• 10.4. Radiation Enteritis
• 10.5. Tumor Resection

11. Short Bowel Syndrome Market, by End Use

• 11.1. Home Care Facilities
• 11.2. Hospitals
• 11.3. Specialty Clinics
• 11.4. Ambulatory Surgical Centers
• 11.5. Research Institutes

12. Short Bowel Syndrome Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Short Bowel Syndrome Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Short Bowel Syndrome Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Ardelyx, Inc.
• 16.2. Emmaus Life Sciences, Inc.
• 16.3. Hanmi Pharmaceutical Co., Ltd.
• 16.4. Ironwood Pharmaceuticals, Inc.
• 16.5. Merck & Co., Inc.
• 16.6. NorthSea Therapeutics B.V.
• 16.7. Nutrinia Ltd.
• 16.8. OxThera AB
• 16.9. Pfizer Inc.
• 16.10. PhaseBio Pharmaceuticals, Inc.
• 16.11. Sancilio & Company, Inc.
• 16.12. Takeda Pharmaceutical Company Limited
• 16.13. Theriva Biologics, Inc.
• 16.14. Zealand Pharma A/S